Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

FLT3 agonist-Fc fusion protein GS-3583

A fusion protein composed of fms-related tyrosine kinase 3 ligand (FLT3L) and agonist fused to an immunoglobulin (Ig) fragment crystallizable region (Fc region), with potential immunostimulating activity. Upon administration of the FLT3 agonist-Fc fusion protein GS-3583, the FLT3 agonist moiety specifically targets, binds to, and activates FLT3 and, synergistically with other growth factors, stimulates the proliferation and mobilization of bone marrow precursor cells, including CD34+ cells, and dendritic cells (DCs). FLT3 agonist-Fc fusion protein GS-3583 has a longer serum half-life compared with soluble FLT3L.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:FLT3 agonist Fc fusion protein GS-3583
Flt3R agonist GS-3583
Code name:GS 3583
GS-3583
GS3583
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search